Jivan and NimbleGen Partner for Splice Array Market
News Feb 03, 2006
"Jivan is proud to offer its full product line on NimbleGen's flexible and robust microarray platform," said Dr. Subha Srinivasan, CEO of Jivan Biologics (Berkeley, CA).
"This partnership furthers our goal to become the platform-independent solution for high-throughput splice variant analysis."
Dr. Stanley Rose, President and CEO of NimbleGen Systems (Madison, WI), commented, "Our collaboration with Jivan provides yet another example of an emerging measure of genome function or activity being enabled by NimbleGen’s platform."
"This product line nicely complements our whole genome ChIP-chip, CGH, Comparative Genome Sequencing, and Expression offerings, and further expands our integrated analytical capabilities also known as High Definition Genomics."
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE